Here, we extend previous findings by demonstrating molecular responses in patients with pre-PMF and PMF with high and intermediate initial mutant allele burdens indicating that IFN may induce molecular remissions regardless of the MPN diagnosis of CALR mutated patients and their initial tumor load [22]. Here, CALR is linked to myeloproliferative disorder.